IC50 values (MTT upon 72 hours of treatment) for naratuximab emtansine, its payload DM1, and CD37 surface levels by FACS
| Cell line . | MTT assay (72 h) . | MTT assay (72 h) . | FACS . | Cell line . | MTT assay (72 h) . | MTT assay (72 h) . | FACS . |
|---|---|---|---|---|---|---|---|
| Naratuximab emtansine IC50, pM . | DM1-me IC50, pM . | CD37/ISO (log2) . | Naratuximab emtansine IC50, pM . | DM1-me IC50, pM . | CD37/ISO (log2) . | ||
| SU-DHL-16 | 100 | 50 | 4.700 | JVM-2 | 400 | 30 | 2.585 |
| WSU-DLCL2 | 10 000 | 40 | 6.190 | Z-138 | 20 000 | 40 | 1.000 |
| SU-DHL-8 | 40 000 | 30 | 2.807 | GRANTA-519 | 780 | 20 | 4.087 |
| SU-DHL-4 | 200 | 150 | 5.977 | JeKo-1 | 30 | 12 | 2.000 |
| SU-DHL-10 | 50 | 25 | 4.858 | MAVER-1 | 800 | 15 | 4.000 |
| DB | 500 | 100 | 6.845 | SP-53 | 780 | 15 | 5.000 |
| OCI-Ly8 | 50 | 50 | 6.248 | MINO | 150 | 8 | 5.672 |
| OCI-Ly18 | 12 000 | 40 | 5.755 | REC-1 | 100 | 100 | 4.087 |
| OCI-Ly19 | 30 000 | 12 | 1.000 | SP-49 | 12 | 12 | 5.615 |
| SU-DHL-5 | 25 | 15 | 4.392 | UPN1 | 5 | 10 | 3.459 |
| OCI-Ly1 | 0.5 | 40 | 2.000 | KARPAS-1718 | 10 | 8 | 4.755 |
| DoHH2 | 30 000 | 30 | 3.170 | SSK41 | 150 | 10 | 3.459 |
| KARPAS-422 | 300 | 30 | 5.954 | VL51 | 20 000 | 40 | 3.000 |
| RC-K8 | 40 000 | 50 | 6.755 | ESKOL | 400 | 20 | 2.807 |
| VAL | 800 | 30 | 6.209 | HAIR-M | 250 | 40 | 2.322 |
| Farage | 40 | 10 | 6.066 | HC-1 | 780 | 30 | 3.700 |
| SU-DHL-6 | 120 | 20 | 4.644 | PCL-12 | 12 000 | 40 | 2.000 |
| Pfeiffer | 50 000 | 40 | 6.883 | MEC-1 | 15 000 | 50 | 2.000 |
| OCI-Ly7 | 50 | 50 | 6.658 | KARPAS-1106-P | 700 | 10 | 5.781 |
| TOLEDO | 15 000 | 50 | 3.459 | FE-PD | 25 000 | 30 | 1.585 |
| SU-DHL-2 | 3 000 | 40 | 5.672 | KARPAS-299 | 40 000 | 10 | 1.000 |
| RIVA | 150 | 30 | 3.170 | L-82 | 20 000 | 10 | 1.000 |
| OCI-Ly3 | 600 | 30 | 5.170 | Ki-JK | 40 000 | 5 | 1.000 |
| OCI-Ly10 | 250 | 15 | 5.833 | SU-DHL-1 | 30 000 | 8 | 0.000 |
| HBL-1 | 50 | 50 | 2.585 | H9 | 15 000 | 70 | 1.000 |
| TMD8 | 8 000 | 30 | 5.781 | HuT-78 | 13 000 | 100 | 1.585 |
| U-2932 | 15 000 | 30 | 4.585 | Mac-1 | 15 000 | 5 | 1.000 |
| Cell line . | MTT assay (72 h) . | MTT assay (72 h) . | FACS . | Cell line . | MTT assay (72 h) . | MTT assay (72 h) . | FACS . |
|---|---|---|---|---|---|---|---|
| Naratuximab emtansine IC50, pM . | DM1-me IC50, pM . | CD37/ISO (log2) . | Naratuximab emtansine IC50, pM . | DM1-me IC50, pM . | CD37/ISO (log2) . | ||
| SU-DHL-16 | 100 | 50 | 4.700 | JVM-2 | 400 | 30 | 2.585 |
| WSU-DLCL2 | 10 000 | 40 | 6.190 | Z-138 | 20 000 | 40 | 1.000 |
| SU-DHL-8 | 40 000 | 30 | 2.807 | GRANTA-519 | 780 | 20 | 4.087 |
| SU-DHL-4 | 200 | 150 | 5.977 | JeKo-1 | 30 | 12 | 2.000 |
| SU-DHL-10 | 50 | 25 | 4.858 | MAVER-1 | 800 | 15 | 4.000 |
| DB | 500 | 100 | 6.845 | SP-53 | 780 | 15 | 5.000 |
| OCI-Ly8 | 50 | 50 | 6.248 | MINO | 150 | 8 | 5.672 |
| OCI-Ly18 | 12 000 | 40 | 5.755 | REC-1 | 100 | 100 | 4.087 |
| OCI-Ly19 | 30 000 | 12 | 1.000 | SP-49 | 12 | 12 | 5.615 |
| SU-DHL-5 | 25 | 15 | 4.392 | UPN1 | 5 | 10 | 3.459 |
| OCI-Ly1 | 0.5 | 40 | 2.000 | KARPAS-1718 | 10 | 8 | 4.755 |
| DoHH2 | 30 000 | 30 | 3.170 | SSK41 | 150 | 10 | 3.459 |
| KARPAS-422 | 300 | 30 | 5.954 | VL51 | 20 000 | 40 | 3.000 |
| RC-K8 | 40 000 | 50 | 6.755 | ESKOL | 400 | 20 | 2.807 |
| VAL | 800 | 30 | 6.209 | HAIR-M | 250 | 40 | 2.322 |
| Farage | 40 | 10 | 6.066 | HC-1 | 780 | 30 | 3.700 |
| SU-DHL-6 | 120 | 20 | 4.644 | PCL-12 | 12 000 | 40 | 2.000 |
| Pfeiffer | 50 000 | 40 | 6.883 | MEC-1 | 15 000 | 50 | 2.000 |
| OCI-Ly7 | 50 | 50 | 6.658 | KARPAS-1106-P | 700 | 10 | 5.781 |
| TOLEDO | 15 000 | 50 | 3.459 | FE-PD | 25 000 | 30 | 1.585 |
| SU-DHL-2 | 3 000 | 40 | 5.672 | KARPAS-299 | 40 000 | 10 | 1.000 |
| RIVA | 150 | 30 | 3.170 | L-82 | 20 000 | 10 | 1.000 |
| OCI-Ly3 | 600 | 30 | 5.170 | Ki-JK | 40 000 | 5 | 1.000 |
| OCI-Ly10 | 250 | 15 | 5.833 | SU-DHL-1 | 30 000 | 8 | 0.000 |
| HBL-1 | 50 | 50 | 2.585 | H9 | 15 000 | 70 | 1.000 |
| TMD8 | 8 000 | 30 | 5.781 | HuT-78 | 13 000 | 100 | 1.585 |
| U-2932 | 15 000 | 30 | 4.585 | Mac-1 | 15 000 | 5 | 1.000 |
IC50 values were calculated using the 4-parameter log-dose calculation, and all values are in pM. Median fluorescence intense levels of surface CD37 were normalized to isotype, and all values from at least 2 independent experiments.
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide.